Pretreatment characteristics and outcome of the patients (high-risk group) included in the joint analysis
| Characteristics . | LPA 99 trial, N = 104 . | APL 2000 trial, N = 82 . | P . | Adjusted P* . |
|---|---|---|---|---|
| Age, y, median (Q1-Q3) | 34 (21.5-42.5) | 41 (27-51) | .007 | — |
| Age younger than 60 y, no. (%) | 97 (93.3) | 73 (89.0) | .43 | — |
| Male sex, no. (%) | 52 (50.0) | 39 (47.6) | .77 | — |
| WBC, 109/L, median (Q1-Q3) | 27.3 (15.4-54.1) | 30.1 (14.3-58.5) | .89 | — |
| Platelets, 109/L, median (Q1-Q3) | 19 (12-34.5) | 27 (16-54) | .001 | — |
| Fibrinogen level, g/L, median (Q1-Q3) | 1.2 (0.7-1.8) | 1.25 (0.9-1.8) | .22 | — |
| CR, no. (%) | 87 (83.6) | 78 (95.1) | .018 | .001 |
| Deaths in CR, no. (%) | 1/87 (1.1) | 3/78 (3.8) | .24 | .22 |
| Relapses, no. (3-y cumulative incidence, %) | 17/87 (18.5) | 7/78 (9.9) | .12 | .15 |
| Total events, no. (3-y EFS, %) | 35 (67.3) | 14 (82.2) | .023 | .024 |
| Total deaths, no. (3-y OS, %) | 23 (80.8) | 7 (91.5) | .026 | .022 |
| Characteristics . | LPA 99 trial, N = 104 . | APL 2000 trial, N = 82 . | P . | Adjusted P* . |
|---|---|---|---|---|
| Age, y, median (Q1-Q3) | 34 (21.5-42.5) | 41 (27-51) | .007 | — |
| Age younger than 60 y, no. (%) | 97 (93.3) | 73 (89.0) | .43 | — |
| Male sex, no. (%) | 52 (50.0) | 39 (47.6) | .77 | — |
| WBC, 109/L, median (Q1-Q3) | 27.3 (15.4-54.1) | 30.1 (14.3-58.5) | .89 | — |
| Platelets, 109/L, median (Q1-Q3) | 19 (12-34.5) | 27 (16-54) | .001 | — |
| Fibrinogen level, g/L, median (Q1-Q3) | 1.2 (0.7-1.8) | 1.25 (0.9-1.8) | .22 | — |
| CR, no. (%) | 87 (83.6) | 78 (95.1) | .018 | .001 |
| Deaths in CR, no. (%) | 1/87 (1.1) | 3/78 (3.8) | .24 | .22 |
| Relapses, no. (3-y cumulative incidence, %) | 17/87 (18.5) | 7/78 (9.9) | .12 | .15 |
| Total events, no. (3-y EFS, %) | 35 (67.3) | 14 (82.2) | .023 | .024 |
| Total deaths, no. (3-y OS, %) | 23 (80.8) | 7 (91.5) | .026 | .022 |
— indicates not applicable.
Adjusted for age, sex, white blood cell count, and platelet count.